What Is the Long-Term Clinical Efficacy of the Thoraflex™ Hybrid Prosthesis for Aortic Arch Repair?

Frontiers in Cardiovascular Medicine

article

Sven Z. C. P. Tan¹  Matti Jubouri²  Idhrees Mohammed³  Mohamad Bashir³ 

[1] Barts and The London School of Medicine and Dentistry, Queen Mary University of London;Hull York Medical School, University of York;Cardiovascular Department, SRM Institute of Medical Science, Institute of Cardiac & Aortic Disorders, SIMS Hospital;Vascular and Endovascular Surgery, Velindre University NHS Trust, Health Education and Improvement Wales

关键词: frozen elephant trunk (FET);    Thoraflex™;    aortic arch;    dissection (TAAD);    aneurysm;   

DOI  :  10.3389/fcvm.2022.842165

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Background The widespread adoption of the frozen elephant trunk (FET) technique for total arch reconstruction (TAR) in aortic arch aneurysm and dissection has led to the development of numerous commercial single-piece FET devices, each with its own unique design features. One such device, Thoraflex™ Hybrid (Terumo Aortic, Glasgow, Scotland), has enjoyed widespread use since its introduction. We present and appraisal of its long-term clinical efficacy, based on international data. Materials and Methods Pre-, intra-, and postoperative data associated with Thoraflex™ Hybrid implantations for aortic arch dissection, aneurysm, and penetrating atherosclerotic ulcer (PAU) up to April 2019 was gathered and is presented herein. Follow-up data at discharge, 3-, 6-, 12-, 24-, 36-, 48-, 60-, 72-, and 84- months post-implantation are included. Results Data associated with 931 cases of Thoraflex™ Hybrid implantation are included. Mean age at implantation was 63 ± 12 years. 55% of patients included were male. Aortic dissection accounted for 48% ( n = 464) of cases. Mean cardiopulmonary bypass and circulatory arrest durations were 202 +72 and 69 ± 50 min, respectively. 30-day mortality was 0.6% ( n = 6), while overall mortality was 14 (1.5%). Freedom from adverse events at 84 months was 95% ( n = 869). Postoperative complications included neurological deficit, multi-organ failure, cardiorespiratory compromise, and infection. Discussion Thoraflex™ Hybrid's unique design is advantageous in comparison to market alternatives. Our data is consistent with that reported in literature and suggests Thoraflex™ Hybrid is associated with favourable rates of mortality and morbidity. Conclusion Thoraflex™ Hybrid remains a central player in the aortic arch prosthesis market. Its use it widespread and is associated with favourable design features and clinical outcomes relative to market alternatives.

【 授权许可】

CC BY